3597-45-3

Basic information

• Product Name: cortienic acid
• Synonyms: cortienic acid
• CAS NO: 3597-45-3
• Molecular Formula: C₂₀H₂₈O₅
• Molecular Weight: 348.43332
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 3597-45-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 565.9°Cat760mmHg
• Flash Point: 310.1°C
• Appearance: /
• Density: 1.31g/cm³
• Vapor Pressure: 3.66E-15mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
• CAS DataBase Reference: cortienic acid(CAS DataBase Reference)
• NIST Chemistry Reference: cortienic acid(3597-45-3)
• EPA Substance Registry System: cortienic acid(3597-45-3)

Safety Data

• Hazardous Substances Data: 3597-45-3(Hazardous Substances Data)

Usage

Uses

Cortienic Acid is a synthetic steroid modeled based on hydrocortisone (H714615), a glucocorticoid produced by the zona fasciculata of the adrenal gland. Cortienic Acid is developed as a steroidal antiinflammatory agents.

InChI:InChI=1/C20H28O5/c1-18-7-5-12(21)9-11(18)3-4-13-14-6-8-20(25,17(23)24)19(14,2)10-15(22)16(13)18/h9,13-16,22,25H,3-8,10H2,1-2H3,(H,23,24)/t13-,14-,15-,16+,18-,19-,20?/m0/s1

Upstream product

• 50-23-7 HYDROCORTISONE 
• 64-17-5 ethanol 
• 123-91-1 1,4-dioxane 

Downstream Products

• 199331-40-3 etiprednol dicloacetate 
• 382-45-6 adrenosterone 

Relevant articles and documents

Cationic lipid-conjugated hydrocortisone as selective antitumor agent

Hydrocortisone, the endogenously expressed steroidal, hormonal ligand for glucocorticoid receptor (GR), is body's natural anti-inflammatory and xenobiotic metabolizing agent. It has both palliative as well as adverse effects in different cancer patients. Herein, we show that conjugation product of C16-carbon chain-associated cationic lipid and hydrocortisone (namely, HYC16) induces selective toxicity in cancer (e.g. melanoma, breast cancer and lung adenocarcinoma) cells with least toxicity in normal cells, through induction of apoptosis and cell cycle arrest at G2/M phase. Further, significant tumor growth inhibition was observed in syngeneic melanoma tumor model with considerable induction of apoptosis in tumor-associated cells. In contrast to hydrocortisone, significantly higher anti-angiogenic behavior of HYC16 helped in effective tumor shrinkage. This is the first demonstration to convert natural hormone hydrocortisone into a selective bioactive entity possessing anti-tumor effect.

HIGHLY POTENT GLUCOCORTICOIDS

The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.

NITROXY DERIVATIVES OF SOFT STEROIDS

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and an ophthalmic composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of the ophthalmic compositions for treating inflammatory conditions of the palpebral or bulbar conjunctiva, cornea and anterior segment of the globe, and to ameliorate inflammation associated with corneal injury.